30 March 2016 - Dynavax Technologies Corporation announced today that the U.S. FDA has accepted for review the biologics license application for Helplisav-B, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older. The FDA has established September 15, 2016 as the Prescription Drug User Fee Act action date.

For more details, go to: http://investors.dynavax.com/releasedetail.cfm?ReleaseID=962813